AR053895A1 - Aminopirimidinas como moduladores de quinasas - Google Patents

Aminopirimidinas como moduladores de quinasas

Info

Publication number
AR053895A1
AR053895A1 ARP060102426A ARP060102426A AR053895A1 AR 053895 A1 AR053895 A1 AR 053895A1 AR P060102426 A ARP060102426 A AR P060102426A AR P060102426 A ARP060102426 A AR P060102426A AR 053895 A1 AR053895 A1 AR 053895A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
heteroaryl
alkylamino
alkoxy
Prior art date
Application number
ARP060102426A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR053895A1 publication Critical patent/AR053895A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Reivindicacion 1: Un compuesto de formula (1) y N-oxidos, sales aceptables para uso farmacéutico, solvatos, isomeros geométricos e isomeros estereoquímicos del mismo, donde: q es 0, 1 o 2; p es 0 o 1; Q es NH, N(alquilo), O, o un enlace directo; Z es NH, N(alquilo), o CH2; B es fenilo, heteroarilo, o un heteroarilo benzo-fusionado de 1 a 9 miembros; R1 es como se muestra en el resto de formula (2), donde n es 1, 2, 3 o 4; Ra es H, alcoxi, fenoxi, fenilo, heteroarilo sustituido en forma opcional con R5, hidroxilo, amino, alquilamino, dialquilamino, oxazolidinonilo sustituido en forma opcional con R5, pirrolidinonilo sustituido en forma opcional con R5, piperidinonilo sustituido en forma opcional con R5, heterodionilo cíclico sustituido en forma opcional con R5, heterociclilo sustituido en forma opcional con R5, -COORy, -CONRwRx, -N(Rw)CON(Ry)(Rx), -N(Ry)CON(Rw)(Rx), -N(Rw)C(O)ORx, -N(Rw)CORy, -SRy, -SORy, -SO2Ry, -NRwSO2Ry, -NRwSO2Rx, -SO3Ry, -OSO2NRwRx o -SO2NRwRx; R5 es 1, 2 o 3 sustituyentes seleccionados en forma independiente de halogeno, ciano, trifluorometilo, amino, hidroxilo, alcoxi, -C(O)alquilo, -SO2alquilo, -C(O)N(alquilo)2, -alquil C1-4-OH o alquilamino; Rw y Rx se seleccionan en forma independiente de H, alquilo, alquenilo, aralquilo, o heteroaralquilo, o Rw y Rx pueden tomarse juntos en forma opcional para formar un anillo de 5 a 7 miembros, que contiene opcionalmente un resto con heteroátomo seleccionado de O, NH, N(alquilo), SO2, SO, o S; Ry se selecciona de H, alquilo, alquenilo, cicloalquilo, fenilo, aralquilo, heteroaralquilo, o heteroarilo; y R3 es uno o más sustituyentes seleccionados en forma independiente de: H, alquilo, alcoxi, halogeno, alcoxiéter, hidroxilo, tio, nitro, cicloalquilo sustituido en forma opcional con R4, heteroarilo sustituido en forma opcional con R4, alquilamino, heterociclilo sustituido en forma opcional con R4, -O(cicloalquilo), pirrolidinonilo sustituido en forma opcional con R4, fenoxi sustituido en forma opcional con R4, -CN, -OCHF2, -OCF3, -CF3, alquilo halogenado, heteroariloxi sustituido en forma opcional con R4, dialquilamino, -NHSO2alquilo, tioalquilo o -SO2alquilo; donde R4 se selecciona en forma independiente de halogeno, ciano, trifluorometilo, amino, hidroxilo, alcoxi, -C(O)alquilo, -CO2alquilo, -SO2alquilo, -C(O)N(alquilo)2, alquilo o alquilamino.
ARP060102426A 2005-06-10 2006-06-09 Aminopirimidinas como moduladores de quinasas AR053895A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68971705P 2005-06-10 2005-06-10
US75108405P 2005-12-16 2005-12-16

Publications (1)

Publication Number Publication Date
AR053895A1 true AR053895A1 (es) 2007-05-23

Family

ID=36929309

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102426A AR053895A1 (es) 2005-06-10 2006-06-09 Aminopirimidinas como moduladores de quinasas

Country Status (17)

Country Link
US (1) US20060281764A1 (es)
EP (1) EP1896029A1 (es)
JP (1) JP2008543760A (es)
KR (1) KR20080028911A (es)
AR (1) AR053895A1 (es)
AU (1) AU2006258054A1 (es)
BR (1) BRPI0611963A2 (es)
CA (1) CA2611470A1 (es)
EA (1) EA200800015A1 (es)
EC (1) ECSP077991A (es)
GT (1) GT200600248A (es)
IL (1) IL187693A0 (es)
NI (1) NI200700316A (es)
NO (1) NO20080163L (es)
PE (1) PE20070076A1 (es)
TW (1) TW200718693A (es)
WO (1) WO2006135644A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2622372A1 (en) * 2005-09-13 2007-03-22 Palau Pharma, S.A. 2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity
EP2066319B1 (en) 2006-09-08 2012-02-01 F. Hoffmann-La Roche AG Benzotriazole kinase modulators
WO2008039794A1 (en) * 2006-09-25 2008-04-03 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
US20080234332A1 (en) * 2007-03-20 2008-09-25 Xiong Cai Raf kinase inhibitors containing a zinc binding moiety
JP2012508367A (ja) * 2008-11-06 2012-04-05 アムビト ビオスシエンセス コルポラチオン リン酸化型ｆｍｓ関連チロシンキナーゼ３バイオマーカーアッセイ
CN102272120B (zh) * 2008-11-07 2013-12-25 H.隆德贝克有限公司 生物活性酰胺
TWI557127B (zh) 2009-09-04 2016-11-11 百健Ｍａ公司 布魯頓氏酪胺酸激酶抑制劑
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
KR20190035769A (ko) 2016-07-21 2019-04-03 바이오젠 엠에이 인코포레이티드 브루톤 타이로신 카이나제 저해제의 석신에이트 형태 및 조성물
WO2018060689A1 (en) * 2016-09-27 2018-04-05 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of usp30
NZ757081A (en) * 2017-03-16 2023-03-31 Crinetics Pharmaceuticals Inc Somatostatin modulators and uses thereof
US11608335B2 (en) 2018-02-12 2023-03-21 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
AR116424A1 (es) 2018-09-18 2021-05-05 Crinetics Pharmaceuticals Inc Moduladores de la somatostatina y usos de los mismos
TW202115008A (zh) 2019-08-14 2021-04-16 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
CA3207378A1 (en) 2021-02-17 2022-08-25 Yuxin Zhao Crystalline forms of a somatostatin modulator

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1206265B1 (en) * 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
WO2003026665A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors

Also Published As

Publication number Publication date
GT200600248A (es) 2007-03-14
EP1896029A1 (en) 2008-03-12
WO2006135644A1 (en) 2006-12-21
BRPI0611963A2 (pt) 2010-10-13
IL187693A0 (en) 2008-08-07
PE20070076A1 (es) 2007-02-09
AU2006258054A1 (en) 2006-12-21
TW200718693A (en) 2007-05-16
NO20080163L (no) 2008-03-07
EA200800015A1 (ru) 2008-06-30
US20060281764A1 (en) 2006-12-14
JP2008543760A (ja) 2008-12-04
KR20080028911A (ko) 2008-04-02
NI200700316A (es) 2009-03-03
CA2611470A1 (en) 2006-12-21
ECSP077991A (es) 2008-01-23

Similar Documents

Publication Publication Date Title
AR053895A1 (es) Aminopirimidinas como moduladores de quinasas
AR054388A1 (es) Aminopirimidinas como moduladores de quinasas
AR054386A1 (es) Moduladores de quinasas con estructuras de alquiloquinolina y alquilquinazolina
AR057063A1 (es) Moduladores de tienopirimidina y tienopiridina quinasa y composicion farmaceutica
AR055144A1 (es) Inhibidor de secrecion acida
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20060622A1 (es) Derivados de pirimidina como inhibidores de fak
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
DE602005023343D1 (de) Pyrimidinderivate als gpcr-agonisten
AR106778A1 (es) Derivados heterocíclicos activos como plaguicidas con sustituyentes que contienen azufre y ciclopropilo
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
PE20120937A1 (es) Compuestos derivados de quinolina y quinoxalina como agentes antivirales
AR073136A1 (es) Compuestos de pirrol
PE20141691A1 (es) Compuestos con actividad nematicida
UY28121A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos
PE20211472A1 (es) Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas
PE20181144A1 (es) Derivados de heteroarilo como inhibidores de parp
AR055563A1 (es) Compuestos de piridil acido acetico, agente farmaceutico y utilizacion del compuesto para preparar dicho agente
PE20121047A1 (es) Derivados de tiazolilpiperidina como fungicidas
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
AR040626A1 (es) Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy)
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
EA201990279A1 (ru) Гербицидные композиции, содержащие фенилпиримидины
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR103397A1 (es) Oxoborazoles microbicidas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal